Drug intelligence / Profile preview

KD2003

Development stage: Unknown
Lead developer: Kyungdong Pharmaceutical
Modality: Small Molecules

Overview

KD2003 is a small molecule drug candidate being developed by Kyung Dong Pharma for the treatment of urinary system disorders. It is categorized as an Incrementally Modified Drug (IMD), a regulatory classification in South Korea for drugs that have been modified from existing approved products to provide improvements in safety, efficacy, or convenience (such as new salts, formulations, or combinations). As of early 2021, the candidate was in Phase 1 clinical development.

Beyond the preview

Go deeper on KD2003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD2003.

Explore the full profile